March 16, 2026 · JAMA internal medicine · DOI: 10.1001/jamainternmed.2026.0057

Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial

Listen to this summary

This randomized clinical trial aimed to evaluate the effectiveness and safety of extended-release buprenorphine compared to sublingual buprenorphine for treating opioid use disorder in pregnant individuals through 12 months postpartum. The results indicated that extended-release buprenorphine was associated with higher illicit opioid abstinence rates during pregnancy and fewer serious adverse events, while postpartum abstinence rates were similar between the two groups. Overall, the findings support the use of weekly extended-release buprenorphine as a viable treatment option for opioid use disorder in pregnancy.

T John Winhusen, Michelle R Lofwall, Frankie Kropp, Daniel Lewis, Marcela C Smid, Jessica L Young, Candace Hodgkins, Elizabeth E Krans, Zachary Hansen, Elisha M Wachman, Davida M Schiff, Constance Guille, Vania Rudolf, Tara Chowdhury, Lawrence Leeman, Mitra Lewis, Abigail G Matthews, Gerald Cochran, Jacquie King, Christine Wilder, Carmen Rosa

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play